The PET scan of the Colombian man's brain shows little tau in the entorhinal cortex (blue), a region that normally accumulates the damaging protein early in Alzheimer's disease. (Credit: Mass General Brigham)

May 15, 2023 03:18 PM EDTUpdated May 19, 02:37 PM

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Ryan Cross

Senior Science Correspondent

The man from Colombia was a medical mystery. Thousands of people in the country are born with a devastating mutation that causes Alzheimer’s disease, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Colom­bian man's ge­net­ics should have doomed him to Alzheimer's. In­stead, a rare mu­ta­tion of­fers clue to pro­tec­tion

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?